Intellia Therapeutics NTLA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $67.67M+16.9% | $57.88M+51.5% | $38.19M-26.7% | $52.12M+57.7% | ||
| $388.86M-16.6% | $466.31M+7.2% | $435.07M+3.6% | $419.98M+82.8% | ||
| $119.8M-4.8% | $125.83M+8.0% | $116.5M+29.0% | $90.31M+27.0% | ||
| $508.66M-14.1% | $592.14M+7.4% | $551.57M+8.1% | $510.29M+69.6% | ||
| -$440.99M+17.5% | -$534.26M-3.7% | -$515.29M-12.5% | -$458.16M-71.1% | ||
| -651.7%+271pp | -923.1%+426pp | -1,349.2%-470pp | -879%-68.7pp | ||
| $28.3M+85.6% | $15.24M-55.3% | $34.1M+313% | -$16.02M-38,048% | ||
| -$412.69M+20.5% | -$519.02M-7.9% | -$481.19M-1.5% | -$474.19M-77.0% | ||
| -609.9%+287pp | -896.8%+363pp | -1,259.9%-350pp | -909.8%-99.3pp | ||
| -$3.82+27.1% | -$5.24+3.1% | -$5.41+12.2% | -$6.16-63.4% | ||
| -$431.21M+17.7% | -$523.99M-3.5% | -$506.32M-12.4% | -$450.59M-72.7% | ||
| -637.2%+268pp | -905.3%+420pp | -1,325.7%-461pp | -864.5%-75.0pp | ||
| -$440.99M+17.5% | -$534.26M-3.7% | -$515.29M-12.5% | -$458.16M-71.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's income statement data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.